Articles from FUJIFILM Biotechnologies

FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced the appointment of Christiane Bardroff as Chief Business Officer (CBO), effective June 1, 2026. Bardroff will lead commercial and sales, business insights and intelligence, strategic partnerships and global marketing, reporting directly to President and CEO Lars Petersen.

FUJIFILM Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today unveils ShunzymeX precision purification technology, which simplifies downstream processing for complex biologics. The technology will be presented this week at the Festival of Biologics conference in San Diego.

FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, is proud to celebrate that its president and CEO Lars Petersen has been named “CEO of the Year” at the CPHI Pharma Awards 2025 in Frankfurt, Germany. The annual global CPHI event brings together 62,000 professionals from the entire pharmaceutical supply chain.

FUJIFILM Biotechnologies today celebrated the grand opening of its manufacturing site in Holly Springs, North Carolina. The newest addition to FUJIFILM Biotechnologies’ global network represents one of the largest commercial-scale cell culture biomanufacturing sites in North America.

FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initiate manufacturing of argenx’ drug substance for efgartigimod at the Holly Springs, North Carolina, site in 2028.

FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, is pleased to announce the appointment of Samuel Hernandez, Ph.D., as senior vice president and site head for its College Station, Texas facility, effective Monday, August 25. With over two decades of biotechnology and pharmaceutical leadership experience, Dr. Hernandez is poised to lead the Texas site’s approximately 770-strong team to achieve continued growth of cell culture and advanced therapies offerings. The previous site head, Keita Hirabayashi, has been appointed to the position of senior director, Corporate Office and board member of the Texas site.